Uncategorized Archives - Page 7 of 134

ThursdaySep 19, 2024 11:45 am

Astiva Health Enhances Medicare Open Enrollment with Tailored Care and Comprehensive Benefits

Open enrollment provides people with Medicare an opportunity to review options, make changes to coverage. Evaluating network, extra benefits can help individuals make important plan decisions. Astiva Health provides a wide range of valuable extra benefits, leading the industry with its generous grocery allowance and rebate programs, along with transportation services, fitness programs, vision and hearing care, and more. As Medicare open enrollment approaches, eligible individuals have the chance to review their healthcare options and make important decisions about their coverage. Astiva Health, a leading Medicare Advantage Prescription Drug (“MAPD”) health plan, stands out with its extensive network in Southern…

WednesdaySep 11, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference

The H.C. Wainwright 26th Annual Global Investment Conference is being held on-line and in person, Sept. 9-11. Clene management will give a virtual presentation of the company’s most recent achievements and results and will hold one-on-one investor meetings. Lead drug candidate CNM-Au8 has been shown to restore and protect neurological function, offering new hope for patients with neurodegenerative conditions. The company is seeking FDA approval to file a new drug application for CNM-Au8, using the accelerated approval pathway for treatment of ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to…

FridaySep 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets

With a focus on improving mitochondrial health, CNM-Au8® stands out among other therapies by targeting the nicotinamide adenine dinucleotide pathway to restore and protect neurological function. Nearly 2 million Americans are affected by amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”) or Parkinson’s disease. The global therapeutics markets for neurogenerative diseases are projected to grow substantially, driven by the growing prevalence of these conditions, rising geriatric population and the emergence of new therapies. Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function…

WednesdaySep 04, 2024 9:45 am

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

The company is leveraging its extensive network of local partnerships to bring healthcare services directly into communities it serves Astiva is expanding network of activity centers, which are designed to be more than just places for medical care Astiva Health recognizes that true wellness goes beyond treating illness; it requires a proactive approach to health One of the pillars of Astiva Health’s approach to care is cultural responsiveness As the landscape of healthcare continues to shift toward more community-focused and personalized care, Astiva Health is launching a comprehensive community outreach initiative aimed at improving wellness and healthcare access for seniors across Southern…

ThursdayAug 29, 2024 10:30 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will…

WednesdayAug 28, 2024 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients In MS, CNM-Au8 can work in conjunction with…

MondayAug 26, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

The company has released key corporate and business updates and Q2 2024 financial results Clinical trials for both Alzheimer’s and Parkinson’s studies yielded encouraging data for lead compound buntanetap Buntanetap in combination with GLP-1 agonist dulaglutide Trulicity(R) showed increased potential to synergistically enhance cognition The company has obtained a patent and begun manufacturing of a new crystalline form of buntanetap, with improved properties Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

TuesdayAug 20, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Astiva Health Enhances Medicare Open Enrollment with Tailored Care and Comprehensive Benefits

Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference

Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets

Astiva Health Inc. Unveils New Community Outreach Initiative to Enhance Senior Wellness, Access to Care

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search